Results 31 to 40 of about 12,153 (191)

Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang

open access: yesBMC Gastroenterology, 2020
Background There are obviously ethnic differences between the UGT1A1 gene polymorphisms. Due to the difference of genetic background and environment, the treatment with colorectal cancer patients of Guangxi Zhuang should not completely follow the ...
Shaojun Chen   +10 more
doaj   +1 more source

Association between UGT1A1*28 polymorphisms and clinical outcomes of irinotecan-based chemotherapies in colorectal cancer: a meta-analysis in Caucasians. [PDF]

open access: yesPLoS ONE, 2013
Whether UGT1A1*28 genotype is associated with clinical outcomes of irinotecan (IRI)-based chemotherapy in Colorectal cancer (CRC) is an important gap in existing knowledge to inform clinical utility.
Xiang Liu   +4 more
doaj   +1 more source

Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis

open access: yesBMC Cancer, 2017
Background To evaluate a new UGT1A and DPYD polymorphism panel to better predict irinotecan-induced toxicity and the clinical response in Chinese patients with metastatic colorectal cancer (mCRC).
Dan Liu   +5 more
doaj   +1 more source

UGT1A1 mutation association with increased bilirubin levels and severity of unconjugated hyperbilirubinemia in ABO incompatible newborns of China

open access: yesBMC Pediatrics, 2021
Background Neonatal hyperbilirubinemia causing jaundice is common in East Asian population. Uridine diphosphate glucuronosyltransferase isoenzyme (UGT1A1) glucuronidates bilirubin and converts the toxic form of bilirubin to its nontoxic form.
Hui Yang   +9 more
doaj   +1 more source

Dutch pharmacogenetics working group (DPWG) guideline for the gene–drug interaction between UGT1A1 and irinotecan [PDF]

open access: yes, 2022
The Dutch Pharmacogenetics Working Group (DPWG) aims to facilitate PGx implementation by developing evidence-based pharmacogenetics guidelines to optimize pharmacotherapy.
van Schaik, Ron H N   +60 more
core   +1 more source

Image_1_Profiling of UGT1A1*6, UGT1A1*60, UGT1A1*93, and UGT1A1*28 Polymorphisms in Indonesian Neonates With Hyperbilirubinemia Using Multiplex PCR Sequencing.JPEG

open access: yes, 2019
Background: Single nucleotide polymorphism (SNP) variants of the uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) gene have been studied as an important factor in neonatal hyperbilirubinemia (jaundice) severity.
Rinawati Rohsiswatmo (6850202)   +5 more
core   +1 more source

Effect of the genetic mutant G71R in uridine diphosphate-glucuronosyltransferase 1A1 on the conjugation of bilirubin

open access: yesOpen Life Sciences, 2022
We aimed to investigate the effect of the genetic mutant G71R (c. 211G > A) in uridine diphosphate (UDP)-glucuronosyltransferase 1A1 (UGT1A1) on the glucuronidation of unconjugated bilirubin.
Chen Hong   +3 more
doaj   +1 more source

Pharmacogenomic tests in Oncology - finding the right dose

open access: yesBrazilian Journal of Oncology, 2021
A pharmacogenetics/genomics (PGx) anticancer drug testing program is being developed by Kurtz and his group at the Brazilian National Cancer Institute (INCA).
Jeziel Basso, Gilberto Schwartsmann
doaj   +1 more source

Significance of UGT1A1*28 genotype in patients with advanced liver injury caused by chronic hepatitis C [PDF]

open access: yesJournal of Medical Biochemistry, 2019
Background: Chronic hepatitis C (CHC) is a significant cause of liver related morbidity and mortality worldwide. The role of genetics in the host response to hepatitis C virus is not elucidated. Genetic variations in UGT1A1 gene are the most common cause
Jordović Jelena   +13 more
doaj  

Study of polymorphisms of UGT1A1 and DPYD genes in chemotherapy for colorectal cancer

open access: yesСибирский онкологический журнал, 2019
Background. The personalized approach implies an individual choice of medicines and their doses for the patient, providing the most effective and safe pharmacotherapy. Objective: analysis of the frequencies of UGT1A1 and DPYD polymorphisms and comparison
N. N. Timoshkina   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy